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B anned in 1975 for a lethal side effect, clozapine re-entered the US market in 1989 because of its superior efficacy in alleviating both positive and negative symptoms of refractory schizophrenia 1 and overall quality of life in patients with treatment-resistant schizophrenia. 2 In a meta-analysis of 7 randomized, controlled clinical trials, patients on clozapine showed superior improvement in BPRS. 3 Typically, a 20% reduction 4, 5 in total BPRS score is the cut-off for a favourable clinical response, but others set the threshold as high as a 40% decrease in BPRS ratings. 6 In the Clinical Antipsychotic Trials of Intervention Effectiveness trials, clozapine displayed superior efficacy in reducing total PANSS scores compared with risperidone and quetiapine (but not against olanzapine). 7 The Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study trial reported that clozapine is more efficacious in treatment-resistant schizophrenia, compared with other second-generation antipsychotics, when switching from a previous one. 8 Schizophrenia is considered a risk factor in the commission of violent and aggressive crimes in general, particularly intractable schizophrenia patients. 9, 10 The treatment of violence in people with psychoses is less successful than in those with mood disorders 11 and therefore good symptom management works in the interest of public safety. Among treatmentresistant and patients with mental retardation, clozapine's role as an antiaggressive agent beyond its antipsychotic effect is already known. 9, 12 Clozapine reduces self-directed 13 and other-directed aggression. 14 The antiaggression onset of action is debated to be between 6 weeks to 9 months treatment initiation. 15 Clozapine has been portrayed to have specific antihostility properties based on its distinct mechanism of concurrently decreasing (5-HT 2 antagonism) and enhancing (5-HT 1B ) serotonergic transmission. 12, 16 In light of its positive effect in aggression control, its beneficial use in prisons, and especially in treating violent and psychotic prisoners, becomes clear. Glazer and Dickson 17 reviewed studies in prisons among offenders with schizophrenia that show aggressiveness and violence reduction as reflected by various functional outcomes. Some of these outcomes are: gaining more institutional privileges; being released to a lower security unit; shorter time spent on restraints; and, fewer incidents of verbal and physical aggression. Frankle et al 18 followed outpatients (n = 165) with criminal records in Massachusetts, dividing them into those treated with clozapine and those not. Using a Poisson regression analysis, the single greatest contributor to a reduction in arrest rate was clozapine prescription-a more important determinant than sex, education level, onset of illness, and recency of birth (regardless of age). 18 Previous studies of functional outcomes in prison used nonstandard or proxy measures such as, for example, a reduction of security levels. 17 In Canada, because the ultimate goal of the correctional system is to reintegrate inmates into society, it is important to use not only clinical indicators but also variables that reflect sustained effects, which in turn might predict postrelease outcomes. For this reason, our study used variables that plausibly indicate postrelease behaviour: change in institutional pay levels (a measure of employability) and a count of institutional offences (a measure of law compliance).
The purpose of our study was to relate clinical outcomes with institutional performance and behaviour among clozapine-treated inpatients in a Corrections Canada forensic psychiatric hospital, located in Saskatoon. This facility is dedicated to high-risk, high-need, federally sentenced (2 years or more) mentally disordered offenders.
Method
This is a naturalistic study based on a review of hospital charts generating clinical outcomes together as well as querying of institutional infractions and pay levels. As the hospital houses prisoners, infractions such as verbal assaults, physical assaults, and rule-breaking are recorded separately and continually by corrections officers. Only subjects with recorded final diagnoses confirmed clinically by a panel of 2 research psychiatrists were included in the study. Diagnoses included psychoses or related disorders according to the DSM-IV. Two groups were compared: those on clozapine and those on other antipsychotic medications. The former included all patients prescribed clozapine since the inception of the centre in 1978. A minimum of 6 weeks of clozapine administration was used as the cut-off criterion for inclusion. In all, 65 patients fulfilled the DSM-IV and duration criteria for clozapine in the period from 1984 to 2005.
Patients on clozapine (n = 65) were matched to a comparison group of patients (n = 33) admitted during the same period. Initially, there were 65 patients in the comparison group but this number was whittled down to 33 because the rest did not meet the DSM criteria for psychosis. This comparison group had never been on clozapine but were required to have been on any other antipsychotic medication for at least 6 weeks. The selected patients (n = 33) were comprised of those on quetiapine (n = 14), olanzapine (n = 10), risperidone (n = 9), methotrimeprazine (n = 2), and chlorpromazine (n = 2). The sum of these numbers is not 33 because some patients were on more than one antipsychotic. The total sample (n = 98) was comprised of those on clozapine (n = 65) and those on other antipsychotics (n = 33). The medical and infractions databases, OMS-a computerized network of all collected information on all aspects of correctional history and progress of offenders, were queried to obtain needed variables.
Demographic, clinical, and infractions information of all patients were entered into a Microsoft Excel spreadsheet and subsequently entered into SPSS software (SSPS Inc, Chicago, IL). Demographic data included highest educational level reached, employment prior to incarceration, and age at first conviction. Clinical data included comorbid substance abuse diagnosis, age at the start of the antipsychotic treatment, overall BPRS score at the start and at the end of 6 months of antipsychotic treatment, number of adjuvant medications taken, and the number of times the patient refused to take medication at the first and sixth month of treatment. This latter measure defined compliance with medication. Noncompliance data were collected from medication administration records, as nurses tally incidents such as refusal to take medication when offered at different times per day. Clinical outcome variables were: the frequency of noncompliant incidents per patient; and, change in BPRS total scores. Trained staffs routinely score the BPRS on all patients at admission, every week in the acute phase, and monthly thereafter when patients are more stable. The validity of the BPRS rating system in the centre is reported by Greenwood and Burt 19 who identified extensive and periodic refresher training as the basis for reliable BPRS ratings.
The history of institutional infractions per patient and the pay levels covering the entire period of incarceration are inputted in the OMS database by corrections officers. For the purpose of our study, a count of institutional infractions was extracted from the OMS system for each patient at 1 year before and 1 year after drug treatment. Although infractions during the drug treatment period were also recorded, these were not included in the analysis, which follows a mirror-image format of before and after. The rationale behind this approach is to rule out differing response rates to medication between groups. The pay level, a plausible measure of institutional adjustment and employability, was compared before and after the treatment period. There are 7 possible levels of pay, with advancement from one to another conditional on institutional behaviour. There is a pay re-evaluation every 3 to 6 months by the nonclinical team of parole and corrections officers, with clinicians blind to the process. These pay levels are, in ascending order, 0, 1, 2, D, C, B, and A, and are not equally spaced apart. The use of a log-linear analysis to compare the proportion of inmates at each of the 7 pay levels between the 2 drug groups was ruled out because of the relatively low number of subjects and the predominance of sparse cells (data not shown). Therefore, change in pay was modelled as a dichotomous variable, where a pay increase was coded as 1, and no increase as 0. As this process is entirely independent from clinical assessments, it serves the useful function of an independent measure of drug efficacy.
Bivariate tests were carried out on demographic categorical variables (for example, substance abuse comorbidity, educational levels, employment before incarceration, and length of stay at the RPC) to ensure the baseline comparability of the groups. Chi-square tests were used, and, when expected frequency counts were below 5 in a given cell, Fisher's exact test was used instead. The Kruskal-Wallis test was used to compare the proportion of people in each educational category. For the BPRS ratings, a repeated measures ANOVA was performed to compare pre-and posttreatment scores for both groups. For the change in pay outcome variable, a follow-up logistic regression was carried out to determine possible predictors.
The histogram of posttreatment infractions (figure not shown) resembled a Poisson distribution that was slightly overdispersed. Hence the negative binomial regression was used because, unlike in Poisson regression, this technique allows for the variance not to equal the mean. All statistical analyses were done using SPSS version 15, except for the negative binomial regression, which was carried out with SPSS version 16.
Our study was approved by the University of Saskatchewan Behavioural Ethics Board and subsequently approved by the Correctional Services of Canada Ethics Review Committee in Ottawa, which recognizes the consent of patients entering the treatment program as sufficient to allow aggregate data collection for review and evaluation of such a program. As such, subjects did not provide a special consent for the study.
Results

Clinical Outcome Variables
As indicated in Table 1 , patients in the 2 medication groups did not differ in most respects, except for mean BPRS scores after drug treatment in which the nonclozapine group attained a significantly lower mean. In the repeated measures ANOVA with BPRS scores as outcome variable, and Time (pre-and posttreatment) and Drug Group (clozapine and nonclozapine) as predictors, the main effect of Time and Drug Group were significant (F = 5.43, df = 1,57, P = 0.02 and F = 5.44, df = 1,57, P = 0.02, respectively. The interaction of Drug´Time was not significant (P = 0.46). Thus the BPRS scores decreased significantly after the drug treatment for both groups (main effect of Time) and the nonclozapine subjects had a significantly greater decrease (main effect of Drug).
Among the nonclozapine patients (n = 33), 31 had medication compliance records. By contrast, of the clozapine patients (n = 65), only 31 had available medication compliance records. The rates of noncompliance were difficult to compare owing to the high percentage of missing data mostly concentrated on the clozapine group. Thus generalizability is affected by the pattern of missing data, which fell into the missing-not-at-random category. Therefore, we dropped compliance rates from any subsequent analysis.
In the Canadian corrections system, performance reviews held every 3 to 6 months could result in a pay level increase (or decrease) for inmates. Collapsing the 7 pay levels into a dichotomy was a procedure that was judged to be worth the loss of information because it allows for a follow-up logistic regression analysis. Table 2A summarizes the change in pay at 6 months after drug treatment. Table 2B gives the details of the change (that is, how many levels and in what direction the change involved) in Table 2A .
The chi-square test revealed a significant association between drug group and pay levels (c 2 = 6.95, df = 1, P = 0.008). The odds ratio for a pay increase between clozapine and nonclozapine groups was 3.13 (95% CI 1.3 to 7.53, P = 0.01). As a follow-up, a conditional forward stepwise logistic regression was done, with pay as the outcome and demographic and clinical variables (listed in Table 1 ) as possible predictor variables. In particular, age at first conviction, age at start of drug treatment, completion of elementary school (Grade 12), length of stay at the RPC, pre-and postdrug BPRS scores, employment prior to incarceration, and type of medication prescribed were entered as possible determinants. Only age at start of medication (Wald = 4.26, df = 1, P = 0.04) and type of medication prescribed (Wald = 5.71, df = 1, P = 0.02) were significant predictors of postdrug pay. Each additional year of age decreased the odds of a pay increase by 7%. Patients on clozapine were more than four times more likely to get a pay increase.
The negative binomial regression model predicting the postmedication count of institutional offences with drug, age at treatment, and premedication offence count was statistically significant with likelihood ratio (c 2 = 31.75, df = 3, P < 0.001). Each predictor was statistically significant ( 
Discussion
Clozapine had positive effects on functional and correctional variables such as pay level and count of infractions. Pay level change for institutional employment was superior in the clozapine group. As Table 2B shows, the clozapine group had a greater variability in pay change (2 decreases, but 7 with more than 1 pay level increase). To our knowledge, this is the only study exploring an association between drug treatment and institutional pay levels. Pay level is a good measure of overall inmate adjustment to the corrections system because it rewards both clinical (that is, compliance with medication and mental stability) and functional outcomes (employability and good institutional adjustment). Pay is a high-threshold measure in the sense that good behaviour is more difficult to fake or misrepresent, compared with answers in a pencil and paper test. Importantly, pay is determined by corrections officers who are oblivious to the clinical assessment done by the clinical treatment team (for example, psychiatrists) so it constitutes independent judgment of an inmate's good behaviour. It is surprising that none of the sociodemographic factors (for example, age at first conviction and education) or the BPRS turned out as significant predictors of pay increase, because these factors also predict offender dangerousness in the Glazer and Dickson 17 study. By the varying mechanisms of reducing positive and negative symptoms of psychosis, and other indications, clozapine may improve functional measures. 17, 20, 21 A hostility decrease 18, 20 and better quality of life 2,10 may also contribute to the improved functioning as evidenced by increased employability. The rehabilitative approach of the RPC's treatment model and our results suggest that employment during incarceration is important and the incentives of pay in a proxy economy, to afford basic institutional coping necessities such as cigarettes, may be present in addition to clozapine's effect.
In our study, clozapine's reduction of BPRS symptoms appeared to be not as effective as that in the nonclozapine group as shown by the significant main effect of Drug. The mean reduction in BPRS total score after 6 months was 10%, compared with the 20% mean reduction among patients not on clozapine, where the baseline levels of the 2 groups did not differ significantly. Kane et al 14 defined clinical response as a 20% decrease in BPRS total score, compared with baseline plus a BPRS score of 36 or less. 4 Both of these measures were surpassed by patients in the nonclozapine group. It is worth mentioning that in the Kane et al study, the patients benefitting much from clozapine treatment had higher BPRS scores at the outset (more than 60), while only 5 of 98 patients met this criterion in our study. The lower BPRS scores prior to the start of the respective antipsychotic medication may be due to other psychological treatments used in the RPC. Treatment with other psychotropic medication before clozapine is the norm as determined by institutional guidelines. Given the naturalistic nature of the study, the length of time spent at the RPC before the start of drug treatment was not controlled. Hence it is possible that clozapine patients who had longer mean length of stay in the hospital already had reduced baseline BPRS scores. Compliance with medication, a factor in reducing BPRS scores, is difficult to assert. At the very least, inpatient compliance with medication, afforded through nursing supervision at medication times, is better than self-administration on an outpatient basis.
The relative decrease in institutional infraction attributable to clozapine is consistent with other studies finding a significant decrease in aggressive acts in the 6 months following the initiation of treatment. 21, 22 Glazer and Dickson 17 found a similar correlation and suggested that the best predictor of future behaviour is past behaviour. In particular, people with a greater level of aggression at referral are more likely to inflict injury in the future. Their finding is consistent with our finding that pretreatment institutional offending is a significant predictor of posttreatment offending. The result of our negative binomial regression model with age, pretreatment offending, and the use of clozapine as significant predictors of future offending agrees with a previous study's 18 finding on a reduction of arrest rates linked with clozapine. The antihostility property of clozapine reported as relating to its 5-HT receptor antagonism, modulation of impulsivity, and the decreased level of akathisia may be evident in this population. 20, 21 Likewise, the uneven impact of clozapine on clinical psychopathology (BPRS) and on correctional outcomes (for example, pay level and infractions) in our study is consistent with a double-blind, randomized study comparing clozapine, olanzapine and haloperidol. In that study, the patients did not differ significantly in psychiatric symptoms as measured by PANSS, even though clozapine did better against both in reducing physical aggression. 23 Chow et al 16 equally showed unchanged PANSS scores among aggressive psychotic patients on clozapine (n = 15) whose MOAS improved from baseline, concluding that clozapines's antiaggressive effect may be independent from its antipsychotic effect. Recently, Krakowski et al 24 compared cognitive enhancement and antiaggressive effects of olanzapine, haloperidol, and clozapine among schizophrenic patients. While both clozapine and olanzapine patients had reduced aggression as measured by MOAS, the reduced aggression in olanzapine patients was related to cognitive enhancement, but not in clozapine patients. That study suggested that clozapine's antiaggressive effect may come at the expense of some cognitive functions. In our study, clozapine's superior antiaggression effect was not accompanied by superior improvement in BPRS scores.
Our study's strength is the availability of infraction and pay level records in a common environment shared by all inmates and which we could relate with clinical outcomes. In community-based studies, such as that of Frankle et al, 18 it is possible that the lower arrest rates of clozapine patients resulted from variability in law enforcement. As a naturalistic study, there are some limitations that need to be acknowledged. These include specific nondiagnosis indications or criteria for the prescribed medications, refractoriness of the symptoms, compliance with medication, level of aggressiveness, and the length of time that patients remained on medication beyond the 6-month treatment period. Second, the effect of polypharmacy relating to additional psychotropic medication to the 2-drug group is a real one in this population. Third, we had a relatively small sample size (n = 98), and the clozapine group outnumbered the nonclozapine group 2 to 1. This limitation led us to collapse the pay level variable into a dichotomy to allow an analysis. Finally, it would be helpful to segregate institutional offending into aggressive and nonaggressive categories, as our results leave the possibility open that the few offences by patients on clozapine may turn out to be the most violent ones. Such information will assist in the management of aggressive offenders before release into the community. It also has the potential of adding to the armamentarium of reducing recidivism and increasing the successful reintegration of mentally disordered offenders.
Conclusion
Our results suggest that clozapine has distinct clinical and institutional adjustment outcomes on mentally disordered offenders with psychosis. While all offenders improved their clinical outcomes, those on clozapine were more likely to be employable and commit fewer infractions. In contrast, offenders on other antipsychotics showed a greater improvement in the management of symptoms.
